![]() I will be placing the report in the Libraries of the House. Background: Bacterial expression systems remain a widely used host for recombinant protein production. S Cartwright & Sons (Coachbuilders) Limited Commonly these include global market conditions realisation through the due diligence process that the project could not be supported (including on state aid grounds) and changes in senior management or parent company strategy.Ī list of bids that withdrew during the 14-15 reporting year is below. Publication number: 20140161835 Abstract: The. ![]() Foster, Jorge Garcia-Lara STAPHYLOCOCCUS AUREUS DIV1B FOR USE AS VACCINE. As of 31 March 2015, RGF beneficiaries had delivered 141,000 monitored jobs.Īs well as reporting on the outcomes achieved against those operational projects and programmes, we are also publishing a list of 16 projects and programmes that have withdrawn since the last Annual Monitoring Report.īidders may withdraw a project or programme for a number of reasons. Assignee: Absynth Biologics Limited Inventors: Simon J. proprietary Clostridium difficile vaccine antigens. This brings the total funding paid by RGF to £1.53 billion, which has leveraged £4.63 billion in private sector investment. vaccine targets in Escherichia coli: a case study presentation utilising Absynth Biologics Ltd. £924 million of RGF support reached companies in 2014-15. The report focuses on the delivery of RGF investment, jobs created and safeguarded by the RGF, and private sector investment leveraged. It covers Rounds 1-5, including projects funded under the Exceptional RGF, up to 31 March 2015. This is the third RGF Annual Monitoring Report. Absynth Biologics discovers and develops vaccines to prevent and treat bacterial infections based on a platform for identifying novel protein antigen targets. The progress made by the Regional Growth Fund in 2014-15 is set out in the publication of the Annual Monitoring Report. Today I am announcing the publication of the Regional Growth Fund (RGF) 2014-15 Annual Monitoring Report.
0 Comments
Leave a Reply. |